Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
SYDNEY, AUSTRALIA, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announced new data from the investigator-initiated EFTISARC-NEO Phase II study presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting (Poster number P 448).